Risk-benefit profiles of women using tamoxifen for chemoprevention.

@article{Nichols2015RiskbenefitPO,
  title={Risk-benefit profiles of women using tamoxifen for chemoprevention.},
  author={Hazel B Nichols and Lisa A DeRoo and Daniel R Scharf and Dale P Sandler},
  journal={Journal of the National Cancer Institute},
  year={2015},
  volume={107 1},
  pages={354}
}
BACKGROUND Tamoxifen has been US Food and Drug Administration-approved for primary prevention of breast cancer since 1998 but has not been widely adopted, in part because of increased risk of serious side effects. Little is known about the risk-benefit profiles of women who use chemoprevention outside of a clinical trial. We examined characteristics associated with initiation and discontinuation of tamoxifen for primary prevention of breast cancer within a large cohort of women with a first… CONTINUE READING

2 Figures & Tables

Connections & Topics

Mentioned Connections BETA
We identified 788 tamoxifen users and 3131 nonusers matched on age and year of enrollment who had no history of contraindicating factors ( stroke , transient ischemic attack , cataract , endometrial or uterine cancer ) .
We identified 788 tamoxifen users and 3131 nonusers matched on age and year of enrollment who had no history of contraindicating factors ( stroke , transient ischemic attack , cataract , endometrial or uterine cancer ) .
While the majority of women who used tamoxifen for primary prevention of breast cancer were likely to benefit , substantial discontinuation of tamoxifen before five years and use by women at risk of serious side effects may attenuate benefits for breast cancer prevention .
While the majority of women who used tamoxifen for primary prevention of breast cancer were likely to benefit , substantial discontinuation of tamoxifen before five years and use by women at risk of serious side effects may attenuate benefits for breast cancer prevention .
We examined characteristics associated with initiation and discontinuation of tamoxifen for primary prevention of breast cancer within a large cohort of women with a first - degree family history of breast cancer . METHODS .
While the majority of women who used tamoxifen for primary prevention of breast cancer were likely to benefit , substantial discontinuation of tamoxifen before five years and use by women at risk of serious side effects may attenuate benefits for breast cancer prevention .
While the majority of women who used tamoxifen for primary prevention of breast cancer were likely to benefit , substantial discontinuation of tamoxifen before five years and use by women at risk of serious side effects may attenuate benefits for breast cancer prevention .
Tamoxifen has been US Food and Drug Administration - approved for primary prevention of breast cancer since 1998 but has not been widely adopted , in part because of increased risk of serious side effects .
We examined characteristics associated with initiation and discontinuation of tamoxifen for primary prevention of breast cancer within a large cohort of women with a first - degree family history of breast cancer . METHODS .
All Topics